Below is LB Pharmaceuticals' Net Income - what it measures, how it is derived, and where it stands now. The formula components map to line items in reported financial statements. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-63.1 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales. LB Pharmaceuticals' Net Income level is aligned with the latest available accounting data. The data originates from publicly accessible accounting records.
Latest LB Pharmaceuticals' Net Loss Growth Pattern
LB Pharmaceuticals Common's Net Loss over the past 4 years is plotted below. A slightly volatile pattern across the series may reflect cyclical or seasonal influences. The interplay between trend direction and volatility shapes the risk profile of this metric. The annual reporting cadence smooths out intra-year noise, revealing the underlying direction. Year-over-year changes in LB Pharmaceuticals' Net Loss tend to be more stable signals than quarter-over-quarter movements.
Sound valuation of LBRX Stock requires mapping how Net Income interacts with LB Pharmaceuticals' broader financial framework. The interconnected nature of LB Pharmaceuticals' financial accounts means that Net Income movements often cascade to related metrics. A structured correlation view of LB Pharmaceuticals' accounts supports more targeted and efficient financial analysis. These interdependencies support more robust financial models for LB Pharmaceuticals.
Accumulated Other Comprehensive Income is demonstrating a shrinking trend compared to prior periods. As of the last annual report, Accumulated Other Comprehensive Income was 99,900.
Based on the recorded statements, LB Pharmaceuticals Common reported net income of -63.1 Million. The Pharmaceuticals sector average is 118.49% above this level, and the Health Care industry average is 190.09% above. LB Pharmaceuticals is also 111.05% lower than the broader all United States stocks average.
Fundamental Drivers Relationships
Cross-company financial ratios help determine LB Pharmaceuticals's valuation standing. Cross-referencing LB Pharmaceuticals' key ratios against peer benchmarks through ratio comparison sharpens the view on relative valuation and competitive positioning. More Info.
LB Pharmaceuticals Common ranks first in net income among leading competitors. It is rated below average in shares outstanding among leading competitors . Forward estimates place Net Loss near -53.95 Million, implying a shrinking bias. A year ago, LB Pharmaceuticals reported Net Loss at -56.79 Million. Relative ratio analysis evaluates LB Pharmaceuticals's earnings valuation.
Net Income Peer Comparison
Stock peer comparison using Net Income is a widely accepted framework for evaluating LB Pharmaceuticals within its group. Investors who find LB Pharmaceuticals' Net Income more favorable than peers may view LB Pharmaceuticals as attractively valued. Peer dispersion in Net Income across the group provides context for evaluating LB Pharmaceuticals' competitive positioning. This Net Income peer data helps refine the view of LB Pharmaceuticals' relative attractiveness.
LB Pharmaceuticals is currently under evaluation in net income among leading competitors.
LB Pharmaceuticals's operating framework helps explain margin behavior, earnings persistence, and funding capacity. Operating leverage helps explain how sensitive earnings may be to slower demand or higher costs. Latest reported fundamentals for LB Pharmaceuticals include EPS loss of 0.74, which helps frame current operating quality.
LB Pharmaceuticals Common metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Not all fields update in real time. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.